<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuing review</td>
<td>1</td>
</tr>
<tr>
<td>Personnel Information</td>
<td>4</td>
</tr>
<tr>
<td>Subject Checklist</td>
<td>5</td>
</tr>
<tr>
<td>Study Location</td>
<td>5</td>
</tr>
<tr>
<td>General Checklist</td>
<td>6</td>
</tr>
<tr>
<td>Funding</td>
<td>8</td>
</tr>
<tr>
<td>Expedited Paragraphs</td>
<td>8</td>
</tr>
<tr>
<td>Summary, Purpose, Background, Study Procedures</td>
<td>11</td>
</tr>
<tr>
<td>Drugs and Devices</td>
<td>15</td>
</tr>
<tr>
<td>Subject Population (a-d)</td>
<td>17</td>
</tr>
<tr>
<td>Subject Population (e-h)</td>
<td>18</td>
</tr>
<tr>
<td>Subject Compensation and Costs, Recruitment Process</td>
<td>19</td>
</tr>
<tr>
<td>Risks</td>
<td>22</td>
</tr>
<tr>
<td>Benefits</td>
<td>23</td>
</tr>
<tr>
<td>Procedures to Maintain Confidentiality</td>
<td>24</td>
</tr>
<tr>
<td>Potential Conflict of Interest</td>
<td>26</td>
</tr>
<tr>
<td>Informed Consent</td>
<td>28</td>
</tr>
<tr>
<td>HIPAA</td>
<td>29</td>
</tr>
<tr>
<td>Attachments</td>
<td>31</td>
</tr>
<tr>
<td>Obligations</td>
<td>33</td>
</tr>
</tbody>
</table>
Timolol Eye Drops in the Treatment of Acute Migraine Headache

Expedited/Full Board Application

UMKC

Protocol # 15-152

Date Printed: 04/18/2018

Protocol Title:
Timolol Eye Drops in the Treatment of Acute Migraine Headache

Protocol Type:
Expedited/Full Board Application

Date Submitted:
03/10/2017

Approval Period:
Draft

Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.

To renew your protocol: 1. Complete this one-page form; 2. If necessary, update any sections of the protocol that need to be updated for the upcoming year (e.g., change in personnel, location) and attach any new supporting documents (e.g., other IRB approval letters); 3. Electronically "sign" the application by clicking in the check box on the "Obligations" page; 4. Remember to click "Submit Form" so that the IRB administrators receive your application. You must answer each question. Input N/A to answer any questions that are not applicable.

NOTE: Documents that contain much of the information required to answer the participant number questions below can be found in the "Event History" section of each protocol.

1. Summary: Number of Participants Associated with the Protocol:

   a. Total number of participants approved to date:
      50

   b. Number of participants studied since the last approval date:
      12

   c. Total number of participants studied since the beginning of the project:
      12

   d. Number of participants remaining to recruit/enroll (total number of participants approved LESS the total number of participants studied to date):
      38

   e. Please explain if there is a discrepancy in participant numbers (e.g., more participants responded to a survey than had been approved):
      na

2a. Reasons and number of withdrawals from the research (both subject and investigator initiated) since the last approval date.

      No withdrawals

b. Number of subjects lost to follow-up since the beginning of the study.

      none
c. Description and number of any protocol deviations/violations or unanticipated problems (UPs)/adverse events (AEs), particularly those that may have affected the risks to subjects since the last approval date.

1 adverse event detailed in a separate report was an incidental branch retinal artery occlusion that occurred on the placebo arm of the study felt to be unrelated to the study.

d. Complaints about the research during the last year.

none

3. A summary of any recent findings, literature, or other relevant information (especially pertaining to risks), if applicable.

No recent developments.

4. Description of the remainder of project:

Y Are research participants still being enrolled in the study?

N Have all enrolled research participants completed study participation?

N Is the research active only for long-term follow-up of enrolled participants?

Y Do you plan to recruit more subjects?

If "No," have all subjects completed all research-related interventions? Note: Protocols must be renewed to continue recruiting participants and/or collect data from already recruited participants.

N Are you in the data analysis stage?

Y Is the data de-identified?

(If you answered yes to these two questions you can stop and submit a Final Report. If you answered no to one of them please continue).

5. Has approval for this study expired?

N

a. Why did approval lapse?

b. What will you do differently in the future to prevent this from happening again?
c. Were any additional research participants enrolled or data collected after the expiration date?

If Yes, describe all activities that continued including number of participants involved and any adverse event or incidents that occurred after expiration of approval.

NOTE: If renewal of the study does not occur before the expiration date of study approval ALL enrollment of participants and DATA COLLECTION must stop at the expiration date. Procedures and treatment needed for the safety of participants should continue but data collected during this time period CANNOT be used for research purposes.

6. Informed Consent:

a. Does this study use a consent form? Y
   (If so please attach a copy of the previously approved "stamped" copy and a clean copy of the consent form)

7. Has there been additional or new information about this study which may affect a subject's willingness to continue their participation, or that may need to be given to prior participants? (Such as safety information, complaints about the research, revised procedures, duration of study, recent literature, etc.)

   If YES, please explain and describe how information was provided or is being provided to current or prior participants.

8. If this is a multi-center trial, has the most recent data safety and monitoring report or other summary report been submitted to the IRB since the last review? N

   If No, submit a current report.

9. Summarize all changes in the protocol since it was last approved (e.g., have you amended your protocol during the past year?). Are you requesting to make any changes for the upcoming year?

   No changes to the study. Research is ongoing.
If necessary, proceed to the appropriate section(s) of the protocol and make your requested changes. Remember that if you are requesting to revise a document that is already attached, you must delete the already attached document and upload the revised document.

10. List of Protocol Sections (and questions) that have been changed/modified.

none.

* * * Personnel Information * * *

Principal Investigator

UMKC defines "Investigator" as an individual who conducts a research study. If the study is conducted by a team of individuals, the Investigator is the responsible leader of the team. Students, fellows and residents may not act as a Principal Investigator.

Name of Principal Investigator: Sean Gratton
Degree (MD/PhD/BSN/etc.): MD
Title: Physician

Email: Sean.Gratton@tmcmath.org
Phone: 8167261073
Fax:

Research Department: School of Medicine
UMKC Status: X Faculty
Check ALL that apply: X Staff
Mailing Address: 2301 Holmes
Other:

ALL research personnel are required to complete Human Subject Research training from CITI within the last 2 years prior to engaging in any research-related activities. Go to CITI Program to complete.

The Research Compliance Office will verify the last date of completion below.

<table>
<thead>
<tr>
<th>CITI Training Date</th>
<th>Type of CITI training completed.</th>
</tr>
</thead>
<tbody>
<tr>
<td>01/25/2017</td>
<td>Group 1 Biomedical</td>
</tr>
</tbody>
</table>

Other Investigator(s)
PROTOCOL
Expedited/Full Board Application
UMKC

Protocol Title: Timolol Eye Drops in the Treatment of Acute Migraine Headache
Protocol Type: Expedited/Full Board Application
Date Submitted: 03/10/2017
Approval Period: Draft
Important Note: This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.

<table>
<thead>
<tr>
<th>Name of Other Investigator</th>
<th>Degree (MD/PhD/BSN/etc.)</th>
<th>Title</th>
<th>Research Department</th>
<th>Type of Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Cossack</td>
<td>MD</td>
<td>Resident</td>
<td>School of Medicine</td>
<td>Co-Investigator</td>
</tr>
<tr>
<td>Edward Nabinsky</td>
<td>BA/MD</td>
<td>Medical Student</td>
<td>School of Medicine</td>
<td>Student Investigator</td>
</tr>
<tr>
<td>Heath Turner</td>
<td>BLA/MD</td>
<td>Student</td>
<td>School of Medicine</td>
<td>Student Investigator</td>
</tr>
</tbody>
</table>

Starred items indicate required fields whenever that section is completed.

** ** Subject Checklist ** **

Subject Checklist

Select All That Apply:
- Children under 18
- Pregnant women
- Fetuses/neonates
- Prisoners
- Military personnel
- Adult Volunteers
  - Economically/educationally disadvantaged
  - Mentally Ill
  - University students
  - University employees
  - Illiterate
  - Homeless
  - Public officials/candidates for public office
  - Institutionalized patients/residents
  - Persons incompetent to give consent (e.g., dementia, comatose, have legal guardians)
  - Healthy Individuals
- Other (please specify):

** ** Study Location ** **
Protocol # 15-152

Protocol Title: Timolol Eye Drops in the Treatment of Acute Migraine Headache
Protocol Type: Expedited/Full Board Application
Date Submitted: 03/10/2017
Approval Period: Draft

Important Note: This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.

Study Location
Select All That Apply - NOTE: Check "Other" and input text: 1.) If your study location is not listed, or 2.) If you would like to list details of your already-checked location (e.g., specific school within a school district)

- UMKC
- Truman Medical Center (TMC)
- Children’s Mercy Hospital (CMH)
- Other University/College
- Other Medical/Health Care Facility
- School/School District
- Other (please specify)

Has this protocol been submitted to any other Institutional Review Board not listed above? N
Is this a multi-site project? (A multi-site study is one where different PIs at different institutions are conducting the same study or aspects of the same study.) N
Will UMKC function as the coordinating center or lead institution? Y
(Please submit an IRB approval or Letter of Permission/Support from TMC or CMH if applicable, and for any site not under the jurisdiction of the UMKC IRBs.)

*** General Checklist ***

Select All That Apply:
- Federally Sponsored Project
- Program Project Grant
- Training Grant
- Industry-Sponsored Clinical Trial
- Project is associated with the School of Public Health (faculty and/or student)
- Cooperating/Collaborating Institution(s) Institution where recruitment will occur OR Institution where Collaborating PI will conduct associated research.
- Interview
- Questionnaire/Survey
Subjects will be compensated for participation

Thesis or Dissertation Project (Please upload proposal and dissertation/thesis committee approval in Attachments section.)

Radioisotopes/radiation-producing machines, even if standard of care

Human blood, cells, tissues, or body fluids

If applicable, PI should check with the IBC Compliance Officer to determine whether or not an application needs to be submitted to IBC

Tissues to be stored for future research projects

If applicable, PI should check with the IBC Compliance Officer to determine whether or not an application needs to be submitted to IBC

Tissues to be sent out of this institution as part of a research agreement

If applicable, PI should check with the IBC Compliance Officer to determine whether or not an application needs to be submitted to IBC

Human Embryos

If applicable, PI should check with the IBC Compliance Officer to determine whether or not an application needs to be submitted to IBC

Human Embryonic Cells? Provide NIH Code Number(s) or state that no federal funding will be used to support this research.

If applicable, PI should check with the IBC Compliance Officer to determine whether or not an application needs to be submitted to IBC

Use of Patient related equipment? If Yes, specify what equipment is being used.

Medical equipment used for human patients/subjects also used on animals. For questions regarding animal use approval, contact Jodi Troup, IACUC Compliance Officer: troupj@umkc.edu or 816 235-5669.

Protocol involves studying potentially addicting drugs.

Investigational drugs, reagents, or chemicals

Commercially available drugs, reagents, or other chemicals administered to subjects (even if they are not being studied)

Investigational Device

This study involves drugs or devices regulated by FDA

Cancer Subjects (e.g., clinical trials, behavior/prevention) or Cancer Tissues (e.g., blood, cells, body fluids).

Is the study posted on www.ClinicalTrials.gov? Y

If Yes, Specify number: NCT02630719

If No, Explain the reason below.

Protected Health Information (PHI) will be viewed, created, accessed, used, or disclosed.

The principal investigator or other research personnel have a financial, personal, or professional conflict of interest related to the study as defined in UMKC’s Conflict of Interest Policy.

Class Project
Other (clarify in text box to the right)

**Funding**

X NONE—This project does not have any funding. If you want to add Funding for the study, please uncheck "NONE."

**Funding**

Add external and internal grant funding source(s) below: Federal Government, Other Gov. (i.e., State, local), Foundation or Other. Select "None" above if there is no external funding for the study.

UM Research Board

Federal Government

Other Gov. (i.e., State, local)

Foundation

Other

Funding for this study was secured by the UMKC Grants Management Office

**Expedited Paragraphs**

PLEASE READ: For Expedited Review, all aspects of the research must include activities that (1) present no more than minimal risk to human subjects, and (2) involve one or more of the specific categories listed below.

Select the following applicable categories to determine if your research project qualifies under Expedited Review. If none of the categories are applicable to your research project, a Full Committee Review will be required. For Expedited or Full Review, proceed to complete the following application. If none of the expedited criteria are appropriate for your project, please move to the next screen WITHOUT checking any of these criteria; your protocol will be reviewed by the full IRB. Note: The IRB will make the final determination if your protocol is eligible for expedited review.

Select one or more of the following paragraph(s):

X 1. Clinical studies of drugs and medical devices only when condition (a) and (b) are met.
   a) Research on drugs for which an investigational new drug application (21 CFR Part 312) is not required. (Note: Research on marketed drugs that significantly increases the risks or decreases the acceptability of the risks associated with the use of the product is not eligible for expedited review.)
   b) Research on medical devices for which
      i) An investigational device exemption application (21 CFR Part 812) is not required; or
      ii) The medical device is cleared/approved for marketing and the medical device is being used in accordance with its cleared/approved labeling.

2. Collection of blood samples by finger stick, heel stick, ear stick, or venipuncture as follows:
   a) From healthy, non-pregnant adults who weigh at least 110 pounds. For these subjects, the amounts drawn may not exceed 550 ml in an 8 week period and collection may not occur more frequently than 2 times per week; or
   b) From other adults and children, considering the age, weight, and health of the subjects, the collection procedure, the amount of blood to be collected, and the frequency with which it will be collected. For these subjects, the amount drawn may not exceed the lesser of 50 ml or 3 ml per kg in an 8 week period and collection may not occur more frequently than 2 times per week.

3. Prospective collection of biological specimens for research purposes by non-invasive means.
Examples:

a) Hair and nail clippings in a non-disfiguring manner;

b) Deciduous teeth at time of exfoliation or if routine patient care indicates a need for extraction;

c) Permanent teeth if routine patient care indicates a need for extraction;

d) Excreta and external secretions (including sweat);

e) Uncannulated saliva collected either in an unstimulated fashion or stimulated by chewing gumbase or wax or by applying a dilute citric solution to the tongue;

f) Placenta removed at delivery;

g) Amniotic fluid obtained at the time of rupture of the membrane prior to or during labor;

h) Supra- and subgingival dental plaque and calculus, provided the collection procedure is not more invasive than routine prophylactic scaling of the teeth and the process is accomplished in accordance with accepted prophylactic techniques;

i) Mucosal and skin cells collected by buccal scraping or swab, skin swab, or mouth washings;

j) Sputum collected after saline mist nebulization.

4. Collection of data through non-invasive procedures (not involving general anesthesia or sedation) routinely employed in clinical practice, excluding procedures involving x-rays or microwaves. Where medical devices are employed, they must be cleared/approved for marketing. (Studies intended to evaluate the safety and effectiveness of the medical device are not generally eligible for expedited review, including studies of cleared medical devices for new indications.)

Examples:

a) Physical sensors that are applied either to the surface of the body or at a distance and do not involve input of significant amounts of energy into the subject or an invasion of the subject's privacy;

b) Weighing or testing sensory acuity;
According to the American Migraine Prevalence and Prevention study, migraine affects 29.5 million Americans[1]. Of those affected by migraine headache, 51% reported reduced work or school productivity; and, as the third leading cause of emergency room visits, migraine headache represents a significant burden for patients and healthcare systems [2,3]. Unfortunately, available treatments for acute migraine are not always effective.

For decades, Timolol eye drops have been readily available and frequently prescribed in the field of ophthalmology. Small case studies have shown promising results for the treatment of acute migraine headaches. The purpose of our research is to conduct a prospective study to investigate the benefit of...
timolol eye drops in those suffering from acute migraine. This study will be a feasibility study for future research with the following aims:
- To identify the efficacy of timolol drops on migraine symptoms
- To identify effective recruitment and retention strategies for conducting a crossover designed migraine study on use of timolol eye drops versus placebo for acute treatment of migraine headaches.

References:

2. Purpose

a) Describe the purpose for the proposed project as well as the hypotheses/research questions to be examined.

To determine differences in those treated with and without timolol eye drops at the onset of an acute migraine headache

1A: To explore differences in severity of symptoms
1B: To explore differences in duration of symptoms
1C: To explore differences in improvement of symptoms
1D: To explore differences in recurrence of symptoms
1E: To explore differences in the need for additional rescue medications to control symptoms

3. Background

a) Relevant Background: Discuss the present knowledge, appropriate literature and rationale for conducting the research. Include the rationale for the selected subject population.

According to the American Migraine Prevalence and Prevention study, migraine affects 29.5 million Americans[1]. Of those affected by migraine headache, 51% reported reduced work or school productivity; and, as the third leading cause of emergency room visits, migraine headache represents a significant burden for patients and healthcare systems [2,3]. Unfortunately, available treatments for acute migraine are not always effective. Current home abortive therapies are limited to nonsteroidal anti-inflammatory medications, caffeine-containing preperations, intranasal lidocaine, isometheptene-containing mediations, intranasal dihydroergotamine and triptan medications[4]. Of these, triptan medications are considered the first line treatment for moderate to severe migraine headache and comprise 80% of prescribed migraine therapy[3]. However, the use of prescription medications, such as triptans and ergotamine, are limited in patients with ischemic heart disease, stroke, uncontrolled hypertension, and certain migraine subtypes. Cases of serotonin syndrome have also been reported with concurrent use of selective serotonin reuptake inhibitors and monoamine oxidase inhibitors; and, the tendency for some prescription medications to trigger rebound headache also compromises management[4,5]. These issues highlight the need for a
convenient abortive migraine home treatment that is both effective and fast-acting.

Oral beta-blockers, such as timolol and propranolol, are both FDA approved for migraine prophylaxis. However, their gradual absorption and modification by first pass metabolism delay effective plasma levels for hours to days, limiting their use in acute migraine[6]. However, timolol eye drops provide a rapid route of delivery, with max plasma concentration achieved within fifteen minutes of administration[7,8]. This pharmacokinetic advantage presents a potential role for timolol eye drops in the management of acute migraine. With this route of administration, the well-known benefits of oral beta-blockers are be available to those with acute migraine headaches. Since 1980, multiple case reports have demonstrated a benefit of beta-blocker eye drops in acute migraine treatment. However to date, no prospective trials have been conducted[5].

Since its approval by the FDA in 1978, timolol eye drops have remained a gold-standard treatment for glaucoma. The long-term and widespread use of beta-blocker eye drops demonstrate its tolerability, safety and high benefit to risk ratio. For those with migraine, this route of administration is easy, convenient, well-studied and tolerated, inexpensive, and readily available. Beta-blocker eye drops may also be a more suitable option for those with co-existing vascular disease, severe nausea and vomiting or high-risk of rebound headache[5].

References:

4. Study Procedures (If this is a student project, the methods section of the thesis or dissertation proposal must be attached in section #16 - Attachment section.)

a) Describe sequentially and in detail ALL procedures in which the research subjects will be involved.

- Include how the data will be collected (i.e. in person or online), number of sessions, amount of time
For school-based research where class time is used, describe in detail the activities planned for non-subjects and explain where both subjects and non-subjects will be located during the research activities.

- Indicate that the instruments used are in the public domain or provide appropriate documentation of permission to use each scale.
- Use any diagrams, charts or tables necessary to make subject participation clear to readers. Attach additional pages if necessary.
- Be sure to identify what procedures are experimental and what are standard of care or established practice for the condition/situation.

Please note: Do NOT respond "See Attachment Section". If you would like to add tables, charts, etc., attach those files in the Attachment section (#16).

For those that meet our inclusion and exclusion criteria:

I. A complete medical history will be obtained
II. A complete baseline ophthalmologic clinic examination within six months of study initiation
III. A complete neurologic clinic examination prior to study initiation
IV. Baseline heart rate and blood pressure measurements
V. Pregnancy Test in any female of child-bearing age and potential
VI. Subjects will then be randomly selected into a study group and control group. The Study group will receive Timolol eye drops. The control group will receive placebo salt-solution eye drops. They are to use their respective drops at the beginnings of an acute migraine. If they do not have relief after using the eye drop, they will proceed to use the usual medication regimen.
VII. Subjects will maintain a migraine dairy that records time of headache onset or onset of headache recurrence. Each headache occurrence will be graded on a headache intensity rating based on a 4 point scale recommended by the IHS (0= no headache, 1= mild headache, 2= moderate headache, 3= severe headache). Also recorded for each headache will be the extent of functional impairment on a 4 point scale (0= function and work normally, 1=mild impairment, 2= severe impairment, 3= requiring bed rest), any associated symptoms (i.e. nausea, vomiting, photophobia, phonophobia), headache recurrences, use of any rescue medications, and adverse effects. At follow up visits, subjects will rate the overall effectiveness of the medication on a 4 point scale (0= poor, 1= fair, 2= good, 3= excellent).
VIII. Subjects will undergo interval clinical monitoring. This will include checking their migraine diaries, checking blood pressure and heart rate.
IX. After two months, all subjects in the study group will switch to the placebo group after a 3 day washout period and all subjects in the placebo group will switch to the study group after a three day washout period. The total study duration will be 4 months per patient. At the termination of the study, patients will fill out an “Exit survey” asking about how they would compare the two drops.

b) Alternative Procedures. Describe alternative procedures, if any, that might be advantageous to the subject. Describe the important potential risks and benefits associated with the alternative procedure(s). Any standard treatment that is being withheld must be disclosed. This information must be included in the consent form.

No standard treatment will be withheld from the patient

c) Will subjects be followed after their active participation is complete? Y
If yes, explain why and describe how:

Subjects will have undergone a neurological exam by TMC Neurologist, Dr. Gratton, who is willing to act as their neurology care provider after completion of the study if desired.

d) Will subjects have access to the study treatment/procedure after completing the study? Y

If yes, explain why and describe how:

If patients benefit from timolol eye drops for their migraine headaches and wish to continue using it as an abortive therapy, this will be an available option.

e) Will subjects be audio recorded? N

f) Will subjects be videotaped? N

g) Will subjects be photographed? N

(Explicit consent must be obtained for the use of any of these methods.)

h) Study Endpoint. What are the guidelines or end points by which you can evaluate the alternative treatments during the study? If one treatment proves to be clearly more effective than another (or others) will the study be terminated before the projected total subject population has been enrolled? When will the study end if no important differences are detected?

Interval efficacy analyses are not planned in this study. The study will enroll for approximately one year.

i) Describe the statistical methods of the research and plans for analysis of the data (i.e. planned statistics, justification of sample size, etc.).

This study is intended to be an exploratory pilot study. Our goal is to enroll about 50 patients: 25 study-first patients and 25 control-first patients (each group will cross over at 2 months). Enrollment will take place for approximately one year. We will then work with a statistician to analyze our data, which include the migraine diary.
### * * * Drugs and Devices * * *

#### 5. Drugs and Devices

**Drugs**

<table>
<thead>
<tr>
<th>Name</th>
<th>IND Number</th>
<th>Type of Research</th>
</tr>
</thead>
<tbody>
<tr>
<td>timolol ophthalmic solution 0.5%</td>
<td></td>
<td>Treatment</td>
</tr>
<tr>
<td>Artificial Tears</td>
<td></td>
<td>Treatment</td>
</tr>
</tbody>
</table>

**Name**

- timolol ophthalmic solution 0.5%

**IND Number (if applicable)**

**Type of Research**

- Treatment

**Name**

- Artificial Tears

**IND Number (if applicable)**

**Type of Research**

- Treatment

**Device**

**Will the study be registered on an online website?**  

Y
If yes, state which website(s):

clinicaltrials.gov

If no, explain why not:

(If the study will be registered on ClinicalTrials.gov, the consent form must contain the required language about it.)

-----------------------------------------------------------------------------------------------

*** Subject Population (a-d) ***

6. Subject Population - In the space below, please detail the participants that you are requesting to recruit (include requested participant number and description of each group requested). (Input N/A if not applicable)

a) Requested Participant Description (include number of participants that you plan to study and description of each group requested, if applicable).

- Number of subjects: 50 (25 control-first, 25 study-first)
- Older than 18 year of age
- Subjects must meet the IHS criteria for migraine headache as defined below:

Migraine criteria per the International Headache Society (IHS):
A. At least 5 (attacks fulfilling criteria B-D
B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)
C. Headache has at least two of the following characteristics:
   1. unilateral location
   2. pulsating quality
   3. moderate or severe pain intensity
   4. aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs)
D. During headache at least one of the following:
   1. nausea and/or vomiting
   2. photophobia and phonophobia
   E. Not attributed to another disorder

b) What is the rationale for studying the requested group(s) of participants?
These subjects meet the international headache society criteria for migraine headache. They suffer from recurrent migraine attacks and would most benefit from a convenient, well tolerated home therapy.

c) If women, minorities, or minors are intentionally excluded, a clear compelling rationale must be provided. Examples for not including minors: disease does not occur in children; drug or device would interfere with normal growth and development; etc. X N/A

d) State if any of the subjects are students, employees, or laboratory personnel. They should be presented with the same written informed consent. If compensation is allowed, they should also receive it. X N/A

* * * Subject Population (e-h) * * *

6. Subject Population (Input N/A if not applicable)

e) Inclusion and Exclusion Criteria (e.g., Participants must have 20/20 vision, Participants must be 30-45 years of age, etc.)

Identify inclusion criteria.

Inclusion Criteria
•Older than 18 years of age
•Acute migraine headache with or without aura as classified by IHS as defined below

Migraine criteria per the International Headache Society (IHS):
A.At least 5 attacks fulfilling criteria B-D
B.Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)
C.Headache has at least two of the following characteristics:
1.unilateral location
2.pulsating quality
3.moderate or severe pain intensity
4.aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs)
D.During headache at least one of the following:
1.nausea and/or vomiting
2.photophobia and phonophobia
E.Not attributed to another disorder

Identify exclusion criteria.
Protocol Title: Timolol Eye Drops in the Treatment of Acute Migraine Headache
Protocol Type: Expedited/Full Board Application
Date Submitted: 03/10/2017
Approval Period: Draft
Important Note: This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.

Exclusion Criteria
- Under age 18
- Non-migraine headache
- Use of systemic beta-blocker
- Medical history of hypotension, bradycardia, syncope or other significant cardiovascular disease
- Medical history of difficulty breathing, asthma or COPD or other pulmonary disease
- Medical history of glaucoma, ocular hypertension or hypotony, punctal stenosis, current use of other ophthalmic medications
- Previous adverse reaction to timolol or other beta-blockers
- Inability to self-administer eye drop due to physical or cognitive disorders
- Currently pregnant or breast-feeding
- Pregnant in the past year
- An intraocular pressure (IOP) less than 8
- Less than 5 or more than 25 migraines per month

f) Describe any planned screening procedures. Attach your screening document(s) (e.g., health history questionnaire) in the Attachment Section (#16).

We will be performing complete ophthalmic and neurologic examinations on subjects prior to enrollment. Heart rate and blood pressure measurements will also be obtained and document prior to enrollment. Pregnancy tests will be administered to women of child bearing age and potential. Patients will be asked if there are any specific health concerns as established in our exclusion criteria.

g) Will bilingual or multilingual subjects be recruited? Y

h) Will non-English speaking subjects be recruited? N

If yes, state language(s) spoken (other than English):

**Subject Compensation and Costs, Recruitment Process**

7. Subject Compensation and Costs Section

a) Will subjects receive compensation for participation? N

Total amount (in dollars or equivalent)

b) Form of Compensation:

- X N/A
c) Describe the remuneration plan (Include when subjects will be paid, whether payment will be prorated and whether a 1099 will be issued.)

N/A

d) For raffles include the number of prizes, nature and value of each prize.

N/A

e) For course or extra credit, describe the available alternatives to participation in the research.

N/A

f) Will subjects or their health care providers be required to pay for any study related procedures or products? N

If yes, explain:

g) Who is responsible for costs incurred due to injury/harm?

While we appreciate people who participate by being in research studies. It is not our policy to pay for or provide medical treatment for persons who participate in studies. This will be detailed in the informed consent.

8. Recruitment Process:

a) Describe the step-by-step procedures for identifying and recruiting potential research subjects or requesting pre-existing data or materials.
PROTOCOL  
Expedited/Full Board Application  
UMKC  

**Protocol Title:** Timolol Eye Drops in the Treatment of Acute Migraine Headache  
**Protocol Type:** Expedited/Full Board Application  
**Date Submitted:** 03/10/2017  
**Approval Period:** Draft  
**Important Note:** This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.

- List any specific agencies or institutions that will provide access to prospective subjects.  
- Identify who will contact prospective subjects and how.

| 1. Established TMC neurology or ophthalmology patients  
2. Listing on Clinicaltrials.gov  
3. Flyer with protocol information and study personnel contact information |

b) Describe solicitation through the use of advertising. (Include plans for using posters, flyers, announcements, newspaper, radio, television or internet ads, face to face interactions, direct mail or phone contact, subject pools, etc.)

| A flyer will be composed with protocol information and study personnel contact information |

c) Planned Subject Identification Methods:

- N/A  
- Direct advertising  
- Chart/database review  
- Living conditions (e.g., nursing home residents)  
- Class participants  
- From PI's own practice/clinic  
- Circumstance (e.g., homelessness)  
- Referrals  
- Organization mailing lists  
- Other (please specify): Established TMC neurology and ophthalmology patients

d) Planned Recruitment Materials/Methods:

- N/A  
- Flyers/posters  
- Phone Scripts  
- Letters to providers/schools/organizations  
- Television ads  
- Newspaper ads  
- Letters to prospective subjects  
- Radio ads  
- Oral Scripts
Protocol Title: Timolol Eye Drops in the Treatment of Acute Migraine Headache

Protocol Type: Expedited/Full Board Application

Date Submitted: 03/10/2017

Approval Period: Draft

Important Note: This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.

-----------------------------------------------------------------------------------------------

PowerPoint presentations

X  Other (please specify):

A flyer will be composed with protocol information and study personnel contact information

*(All advertising must be submitted for review in its final printed/recorded form)

e) Will the PI use a centrally coordinated advertisement program?  N

f) Will a central 800# facility be used for recruitment?  N

If yes, identify the calling company:

Note: Attach copies of ALL recruitment materials in the attachment Section

-----------------------------------------------------------------------------------------------

* * * Risks * * *

9. Risks (Input N/A if not applicable)

US Department of Health & Human Services (HHS) Regulations define a subject at risk as follows: "...any individual who may be exposed to the possibility of injury, including physical, psychological, or social injury, as a consequence of participation as a subject in any research, development, or related activity which departs from the application of those accepted methods necessary to meet his needs, or which increases the ordinary risks of daily life, including the recognized risks inherent in a chosen occupation or field of service."

a) PI's evaluation of the overall level of Risk. (Please check one: minimal or > minimal.)

   Minimal (everyday living)

   Y  > Minimal (greater than everyday living)

b) Discuss the risks of the proposed research. Specify the risks(s) associated with each procedure or test. Consider both physical and psychological/emotional risks. (If applicable, include possible breach of confidentiality.)
Since receiving FDA approval in the 1970s, Timolol eye drops have been safely used as a standard treatment of glaucoma. Unintended side effects have been found to be generally mild and rare. Timolol eye drops may also cause localized eye irritation or decrease intraocular pressure. In susceptible patients, timolol eye drops may cause cardiovascular or pulmonary side effects. Subjects will be screened prior to enrollment to exclude those at risk, according to the current clinical standard of care. Extensive counseling of potential adverse reactions will be discussed with study participants.

c) **How will subjects be assessed for adverse events?**

Subjects will be monitored with scheduled clinical evaluations for the duration of the four month study. This will include intraocular pressure measurements, heart rate and blood pressure monitoring. Patients may also contact us by phone to address any questions or concerns.

d) **Is there a plan to monitor study data for subject safety?**

Y

If yes, discuss who will monitor the study data and describe the monitoring plan:

Subjects will be monitored with scheduled clinical evaluations. This will include intraocular pressure measurement, heart rate and blood pressure monitoring.

e) **Describe the procedures or safeguards in place to protect against or minimize potential risks (e.g., referral to psychological counseling resources).**

• In addition to scheduled follow up examinations, subjects will be able to communicate with us throughout the study, and can let us know right away if they want to stop the study and are uncomfortable during clinical exam.

• In the case of an adverse effect deemed severe by subject or investigator, the subject will be withdrawn from the study.

-------------------------------  * * * Benefits * * *  -------------------------------

10. **Benefits**

a) **Discuss any potential direct benefits to subjects from their involvement in the project that would justify involvement of subjects in this study.**

This study may result in migraine symptom relief in subjects. There are no other direct benefits to the subject.

b) **Discuss any potential indirect benefits to society that would justify involvement of subjects in this study.**

The knowledge and insights emanating from this study will potentially advance research efforts.
surrounding acute migraine headache and ultimately may lead to better treatment of this condition.

c) Briefly assess the risk/benefit ratio of the subject’s participation. (Include consideration of alternative therapy, benefit to the class of patients, and benefits to society. Describe the subjects’ alternatives to participation in the study.)

Since its approval by the FDA in 1978, timolol eye drops have remained a gold-standard treatment for glaucoma. The long-term and widespread use of beta-blocker eye drops demonstrate its tolerability, safety and high benefit to risk ratio. For those with migraine, this route of administration is easy, convenient, well-studied and tolerated, inexpensive, and readily available. Beta-blocker eye drops may also be a more suitable option for those with co-existing vascular disease, severe nausea and vomiting or high-risk of rebound migraines.

* * * Procedures to Maintain Confidentiality * * *

11. Procedures to Maintain Confidentiality

a) If information derived from the study will be provided to the subject’s personal physician, a government agency, or any other person or group (other than the research team), describe to whom the information will be given and the nature of the information, if applicable.

N/A

b) Explain how you will protect subjects’ privacy. Note: Privacy can be defined in terms of having control over the extent, timing, and circumstances of sharing oneself (physically, behaviorally, or intellectually) with others. Please keep this definition in mind as you respond to this item.

To minimize the breach of confidentiality risk, we will not use the subject’s name or hospital number to identify them on any study records. Instead a unique study number will be assigned to each subject. Only this number will be used on study documents that relate to the subject. We will keep the list of subject names and corresponding unique study number in a secure, locked location. the code used to protect subject confidentiality will be stored separately from other study related data. At the end of the project, this list will be destroyed.

c) Describe how you will maintain the confidentiality of subjects’ information. Note: Confidentiality pertains to the treatment of information that an individual has disclosed in a relationship of trust and with the expectation that it will not be divulged to others (without permission) in ways that are inconsistent with the understanding of the original disclosure. Please keep this definition in mind as you respond to this item.

To minimize the breach of confidentiality risk, we will not use the subject’s name or hospital number to identify them on any study records. Instead a unique study number will be assigned to each subject. Only this number will be used on study documents that relate to the subject. We will keep
Protocol Title: Timolol Eye Drops in the Treatment of Acute Migraine Headache
Protocol Type: Expedited/Full Board Application
Date Submitted: 03/10/2017
Approval Period: Draft

Important Note: This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.

The list of subject names and corresponding unique study number in a secure, locked location. The code used to protect subject confidentiality will be stored separately from other study related data. At the end of the project, this list will be destroyed.

d) Who will have access to study records or specimens? (Please identify specific team members by name.)
Sean Gratton MD and Ashley Abraham MD and Matthew Cossack MD and Eddy Nabrunski (UMKC Medical Student)

e) Will data be collected anonymously (i.e., NO identifying information from subjects will be collected, recorded, or linked to the study data)? If not, please explain.
To minimize the breach of confidentiality risk, we will not use the subject’s name or hospital number to identify them on any study records. Instead a unique study number will be assigned to each subject. Only this number will be used on study documents that relate to the subject. We will keep the list of subject names and corresponding unique study number in a secure, locked location. The code used to protect subject confidentiality will be stored separately from other study related data. At the end of the project, this list will be destroyed.

f) If you plan to use existing data, records or specimens, what is the source of the data/records/specimens, and how will you access them? NOTE: "Existing" means data or specimens collected (i.e., on the shelf) prior to the proposed research. It includes data or specimens collected for research and non-research activities.
N/A

g) Will subjects be asked to give permission for release of identifiable data (e.g., information, videotapes), now or in future? If so, explain here and include appropriate statements in consent materials.
No

h) If using existing data/biological specimens, will the researchers have access to a code linking the data to personally identifiable information?
N/A

i) If identifying information will be collected and linked to data/specimens, explain at what stage identifiers will be removed from the data/specimens. If identifiers will be retained, explain why this is necessary and how confidentiality will be protected.
To minimize the breach of confidentiality risk, we will not use the subject’s name or hospital number to identify them on any study records. Instead a unique study number will be assigned to each subject. Only this number will be used on study documents that relate to the subject. We will keep the list of subject names and corresponding unique study number in a secure, locked location. the
code used to protect subject confidentiality will be stored separately from other study related data. At the end of the project, this list will be destroyed.

j) If the data is coded, explain where the key to identifiers will be stored, how it will be protected, and who will have access to it.

The data will be stored in a secure, locked location in the ophthalmology department. Only the research investigators will have access to the information. The code used to protect subject confidentiality will be stored separately from other study related data.

k) Explain why, where, in what format, and for how long data/specimens will be retained. Data storage must comply with UM System data retention and security policies. Please contact UMKC Information Services with questions (email: callcenter@umkc.edu, phone: 816-235-2000).

The data will be maintained on paper charts in a secure, locked location in the ophthalmology department. The code used to protect subject confidentiality will be stored separately from other study related data. Records will be retained for seven (7) years after final report or project has been completed, then destroyed.

-----------------------------------------------------------------------------------------------

** * * * Potential Conflict of Interest * * * **

12. Potential Conflict of Interest

Conflict of Interest and the definitions related to the Conflict of Interest Policy and the following questions, please refer to the Help Screen.

Conflict of Interest: Please check Yes or No for each item below.

a) N Does the research involve a drug, device, or biological invented by you, an immediate family member or other Research Personnel?

b) N Is the research sponsored by an entity with which you, an immediate family member, or other Research Personnel have a paid consulting or advising relationship?

c) N Will you, members of your immediate family, or other Research Personnel receive special compensation or increased compensation if the research generates a favorable outcome?

d) N Will you, members of your immediate family, or other Research Personnel receive any money, gift or anything of monetary value above and beyond the actual costs of enrollment, conduct of the research, and reporting on the results, including, but not limited to, finders fees, referral fees, recruitment bonuses, and an enrollment bonus for reaching
PROTOCOL
Expedited/Full Board Application
UMKC

Protocol Title: Timolol Eye Drops in the Treatment of Acute Migraine Headache
Protocol Type: Expedited/Full Board Application
Date Submitted: 03/10/2017
Approval Period: Draft

Important Note: This Print View may not reflect all comments and contingencies for approval.
Please check the comments section of the online protocol.
Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.

---

to, finders fees, referral fees, recruitment bonuses, and an enrollment bonus for reaching an accrual goal or similar types of payments?

**e)** N Do you, members of your immediate family or other Research Personnel have any other interests or relationships (including volunteer services) that might constitute a conflict of interest or an appearance of conflict of interest in connection with the research project?

**f)** N Will the payment you receive for services provided during the conduct of the research (e.g., investigator and Research Personnel time and tests) be inconsistent with fair market value for those services?

### Significant Financial Interest:

**g)** N Will you, your immediate family members or other Research Personnel receive salaries, royalties and/or other payments for services (e.g., consulting fees, honoraria, research design, management position, independent contractor, service on advisory or review committees, board membership seminars, lectures or teaching engagements when totaled together exceeded $5,000 during the previous 12 months or are expected to exceed $5,000 over the next 12 months)? This excludes reasonable costs of conducting the research, as specified in the research agreement.

**h)** N Do you, your immediate family members, or other Research Personnel hold any ownership interests including stocks, bonds, or stock options that exceed $5,000 and/or that constitute more than a five percent (5%) ownership interest in the sponsoring organization? This does not include any interests held solely by reason of investment in a business by a mutual, pension or other institutional investment fund over which the investigator and/or his or her immediate family do not exercise day-to-day control of investment decisions.

### Minimizing Risks and Disclosure to Subjects

**i)** N Have you disclosed any actual, potential or perceived conflicts of interest in the consent form? Research Personnel are required to disclose all such conflicts to all research participants in the research consent form.

**j)** N What steps, if any, have you taken or will you take to manage the conflict of interest and minimize the risks associated with any actual, potential or perceived conflicts of interest arising out of this research?

---

If you checked Yes to any statement (a-h, except f) above, please identify the research team member(s) below and provide details concerning the potential conflict of interest.

---

By submitting this form, you are attesting that you have read the UMKC HRPP Policy on Conflict of Interest and agree to abide by its terms. You will update this disclosure form when new or changes in conflict of interest arise, and that you will comply with any conflict management plan required by the Institutional Review Board (IRB) to
**Protocol Title:** Timolol Eye Drops in the Treatment of Acute Migraine Headache  
**Protocol Type:** Expedited/Full Board Application  
**Date Submitted:** 03/10/2017  
**Approval Period:** Draft  
**Important Note:** This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.

manage, reduce, or eliminate any actual or potential conflict of interest for the duration of the research.


**Informed Consent**

13. Informed Consent  
See sample consent forms at [http://ors.umkc.edu/research-compliance/irb/irb-forms](http://ors.umkc.edu/research-compliance/irb/irb-forms)

Please provide consent process background information below.

Informed Consent
Title Consent Form
Consent Information Type Consent
Consent Document X Attachment

Will subjects be deceived or be incompletely informed regarding any aspect of this study?
If applicable, describe the type of deception you will use, indicate why it is necessary for this study. Provide a copy of the debriefing script you will use and explain when and how it will be used:
NO

Will informed consent be obtained from all research subjects (and/or their parents or legally authorized representatives)?
YES

Who will obtain subjects’ consent? (Check all that apply)
X Principal Investigator
X Co-Investigator
Study Coordinator
Research assistant(s)
Other research staff
Contracted Data Collection Firm
Other (please specify):

If subjects are not able to give legal consent, explain how and from whom consent will be obtained.
They will not be included in the study

If consent is being obtained from non-English speaking subjects, explain the translation process for all documents seen by subjects, including consent documents. Describe the consent process in these circumstances.
Non-English speakers will not be included in the study
Note: Provide copies of translated and back-translated consent documents and provide the translator’s credentials. Translators must be certified or have proof of cultural competency education/training.)

-----------------------------------------------------------------------------------------------
15. Health Insurance Portability and Accountability Act (HIPAA)

The HIPAA Privacy Rule establishes the right of an individual to authorize a covered entity, such as a health plan, health care clearinghouse or health care provider, to use and disclose his/her Protected Health Information (PHI) for research purposes. The Privacy Rule defines the elements of individual information that comprise PHI and establishes the conditions under which PHI may be used or disclosed by covered entities for research purposes. It also includes provisions to allow an individual’s PHI to be disclosed or used in research without the person’s authorization (i.e., IRB Waiver of HIPAA Requirement Authorization). For more information, consult HIPAA Privacy Rule for Research.

a) Does the study involve the use of PHI from an UMKC covered entity?  N

If yes, please contact your Privacy Board/HIPAA Officer (Please visit http://ors.umkc.edu/research-compliance/hipaa)

b) Does the study involve use of Protected Health Information (PHI) from a covered entity outside of UMKC (i.e. another organization or institution)?  Y

If Yes, explain what arrangements have been made to comply with the HIPAA requirements of the entity from which the PHI will be obtained.

A submission for approval will be submitted to the TMC Privacy Board as well as TMC Office of Research Administration

c) Does the study involve use of a "limited data set"?  N

If Yes, patient authorization for use of the data set is not required; however, you must have a data use agreement in place with the entity from which the data will be obtained as required by HIPAA. Attach a copy of the agreement in the Attachments section

Protected Health Information (PHI) is health information with one or more of the following identifiers. For more information see: http://www.hhs.gov/ocr/hipaa/

1. Names
2. Social Security numbers
3. Telephone numbers
4. All geographic subdivisions smaller than a State, including street address, city, county, precinct, zip code, and their equivalent geocodes, except for the initial three digits of a zip code, if, according to the
current publicly available data from the Bureau of the Census: (1) The geographic unit formed by combining all zip codes with the same three initial digits contains more than 20,000 people; and (2) The initial three digits of a zip code for all such geographic units containing 20,000 or fewer people is changed to 000.

5. All elements of dates (except year) for dates directly related to an individual, including birth date, admission date, discharge date, date of death; and all ages over 89 and all elements of dates (including year) indicative of such age, except that such ages and elements may be aggregated into a single category of age 90 or older.

6. Fax numbers
7. Electronic mail addresses
8. Medical record numbers
9. Health plan beneficiary numbers
10. Account numbers
11. Certificate/license numbers
12. Vehicle identifiers and serial numbers, including license plate numbers
13. Device identifiers and serial numbers
14. Web Universal Resource Locations (URLs)
15. Internet Protocol (IP) address numbers
16. Biometric identifiers, including finger and voice prints
17. Full face photographic images and any comparable images; and
18. Any other unique identifying number, character, or code (note this does not mean the unique code assigned by the Investigator(s) to code the research data)

* * * Attachments * * *

16. Attachments

Attach relevant documents here. These could include:

- Collaborating Investigator's IRB approval and approved documents
- Conflict of Interest information
- Debriefing Script; Grant/Sub-contract
- HIPAA Authorization Form from HIPAA-covered entity
- Interview/Focus Group Questions
- Investigator's Brochure
- Letters of Agreement/Cooperation from organizations who will help with recruitment
- Methodology section of associated Thesis or Dissertation project
- Questionnaires
Protocol Title: Timolol Eye Drops in the Treatment of Acute Migraine Headache
Protocol Type: Expedited/Full Board Application
Date Submitted: 03/10/2017
Approval Period: Draft
Important Note: This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.

- Radiation Control Office approval material
- Recruitment Material (e.g., flyers, email text, verbal scripts)
- Sponsor's Protocol; Surveys
- Other files associated with the protocol (you can upload most standard file formats: xls, pdf, jpg, tif, etc.)

Please be sure to attach all documents associated with your protocol. Failure to attach the files associated with the protocol may result in this protocol being returned to you for completion prior to being reviewed. Students: Be sure to attach the Methods section of your thesis or dissertation proposal. If this protocol is associated with a grant proposal, please remember to attach your grant.

To update or revise any attachments, please delete the existing attachment and upload the revised document to replace it.

<table>
<thead>
<tr>
<th>Document Type</th>
<th>Other Documentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Attachment</td>
<td>migraine journal</td>
</tr>
<tr>
<td>Document Name</td>
<td>migraine journal</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Document Type</th>
<th>Other Documentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Attachment</td>
<td>timolol information sheet</td>
</tr>
<tr>
<td>Document Name</td>
<td>timolol information sheet</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Document Type</th>
<th>Other Documentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Attachment</td>
<td>recruitment script (1)</td>
</tr>
<tr>
<td>Document Name</td>
<td>recruitment script (1)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Document Type</th>
<th>Other Documentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Attachment</td>
<td>Migraine flyer</td>
</tr>
<tr>
<td>Document Name</td>
<td>Migraine flyer</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Document Type</th>
<th>Other Documentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Attachment</td>
<td>Migraine Flyer</td>
</tr>
<tr>
<td>Document Name</td>
<td>Migraine Flyer</td>
</tr>
</tbody>
</table>
**Obligations**

Obligations of the Principal Investigator include the following:

Provide all subjects a copy of the signed consent form, if applicable.

Modifications - Changes in any aspect of the study (for example, project design, procedures, consent forms, advertising materials, additional key personnel or subject population) will be submitted to the IRB for approval before instituting the changes.

Training - Human subject training certificates, including those for any newly added personnel, will be provided for all key personnel. Training must be updated every two (2) years.
PROTOCOL
Expedited/Full Board Application
UMKC

Protocol Title: Timolol Eye Drops in the Treatment of Acute Migraine Headache
Protocol Type: Expedited/Full Board Application
Date Submitted: 03/10/2017
Approval Period: Draft
Important Note: This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.

Submit the Continuing Review Form in order to maintain active status of the approved protocol. This form must be submitted to the IRB at least 30 days (AHSIRB) or 45 days (SSIRB) prior to the date of expiration.

Submit the Protocol Violation Form to report protocol Deviations/Violations or the Event Reporting Form to report Adverse Events (AEs) or Unanticipated Problems that occur in the course of the protocol.

Final Report - The IRB will be notified when the study is complete. To do this, complete the IRB Exempt Report Form and select the "Final Report"

I certify that I have reviewed this application, including attachments and that all information contained herein is accurate to the best of my knowledge. I agree to report any substantive changes to the information contained in this application immediately to the UMKC IRB.

I agree that no subject will be enrolled nor will any data intended only for research use be collected prior to issuance of an IRB approval.

I understand that I am fully responsible for the execution and management of this study and that I am responsible for the performance of any sub-investigators or key personnel including their adherence to all of the applicable policies and regulations.

I understand that for the purposes of the UMKC IRB "anonymous" means the HIPAA definition of de-identified data. (See Help Screen for definition)

I have completed the CITI Human Subjects Research Protection Course and the certificate is either attached to this application. A copy of current CV must also be included.

This study will not begin until the investigator receives written final approval.

X The Principal Investigator has read and agrees to abide by the above obligations.

Please click "Check for Completeness" to your left to continue to the next step. If the protocol is complete and ready for submission, please click "Submit Form" to your left to submit your protocol for IRB Review.

-----------------------------------------------------------------------------------------------